gefapixant Report issue

Small molecule Experimental
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now
Gefapixant (MK-7264) is a drug which acts as an antagonist of the P2RX3 receptor, and may be useful in the treatment of chronic cough. It was named in honour of Geoff Burnstock.   Wikipedia

Chemistry

  • SMILES: COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(=O)(=O)N
  • InChIKey: HLWURFKMDLAKOD-UHFFFAOYSA-N
  • Mol. Mass: 353.4
  • ALogP: 1.21
  • ChEMBL Molecules:
    gefapixant  
    None  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

af-219 | gefapixant

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Asthma (Phase 1)

Cough (Phase 3)

Cystitis, Interstitial (Phase 2)

Healthy Volunteers (Phase 1)

Idiopathic Pulmonary Fibrosis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Pain (Phase 2)

Renal Insufficiency (Phase 1)

Sleep Apnea, Obstructive (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 25
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue